CClinicalTrials.gg
RecruitingNCT07074730Updated Jul 22, 2025

General Anesthesia Versus Spinal Anesthesia With Local Anesthetic Infiltration for Buccal Mucosal Graft in Urethroplasty

An interventional study of Spinal anesthesia and General anesthesia in General Anesthesia, Spinal Anesthesia and Local Anesthetic Infiltration, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to male participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
21 Years and older
Sex
Male
01

Study summary

This study aims to compare general anesthesia and spinal anesthesia with local anesthetic infiltration for buccal mucosal graft (BMG) in urethroplasty.

Read the detailed description

Urethroplasty is a surgical procedure aimed at reconstructing the urethra and is considered the standard treatment for bulbar urethral strictures, with different types of tissues used as either grafts or flaps, affecting approximately 300 per 100,000 males.

Postoperative pain following urethroplasty with buccal mucosal graft (BMG) is primarily related to the oral graft harvest site.

General Anesthesia provides a state of complete unconsciousness, ensuring that patients are free from pain and awareness during the surgery. It can be beneficial in complex cases or when extended manipulation is required, allowing for muscle relaxation and controlled ventilation.

On the other hand, spinal anesthesia involves the injection of anesthesia into the cerebrospinal fluid, resulting in targeted numbness in the lower body. This technique can be advantageous for its fast, simple, cost-effective method, rapid onset, lower risk of systemic complications, and preservation of airway reflexes.

02

Conditions studied

  • General Anesthesia
  • Spinal Anesthesia
  • Local Anesthetic Infiltration
  • Buccal Mucosal Graft
  • Urethroplasty
03

In context

Lead sponsor

Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Male patient age ≥ 21 years.
  • American Society of Anesthesiologists (ASA) classification I-II.
  • Patient scheduled for urethroplasty.

Exclusion criteria

Exclusion Criteria:

  • Patients who are taking analgesics for chronic illness or have a history of substance abuse.
  • Patients who are unable to describe their postoperative pain (e.g., neuropsychiatric disorder).
  • Patients with known local anesthetics and opioid allergy.
  • Patients with infection at the site of the needle puncture.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Group S

    Spinal anesthesia with local anesthetic infiltration.

    Other: Spinal anesthesia

  • Active comparator
    Group G

    General anesthesia.

    Other: General anesthesia

Interventions

  • OtherSpinal anesthesia

    Patients will receive spinal anesthesia with local anesthetic infiltration.

  • OtherGeneral anesthesia

    Patients will receive general anesthesia.

06

What researchers measure

Primary outcomes

  1. Degree of pain

    Each patient will be instructed about postoperative pain assessment with the Numerical rating Scale (NRS). NRS (0 represents "no pain"; (1-3) mild pain; (4-6) moderate pain; (7-10) severe pain. NRS will be assessed at 0, 4, 8, 12, 18 and 24h postoperatively.

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. Postoperative morphine consumption

    Rescue analgesia of morphine will be given as 3 mg bolus if the Numerical rating Scale (NRS)\> 3 to be repeated after 30 min if pain persists until the NRS\< 4.

    Time frame: 24 hours postoperatively

  2. Operative time

    Operative time will be recorded from the induction of anesthesia to discharge to the post-anesthesia care unit (PACU).

    Time frame: Till discharge to post-anesthesia care unit (Up to 2 hours)

  3. Length of hospital stay

    Length of hospital stay will be recorded from admission till the discharge from the hospital.

    Time frame: Till discharge from hospital (Up to one week).

  4. Patient satisfaction

    • Degree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely unsatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied).

    Time frame: 24 hours postoperatively

  5. Incidence of complications

    Incidence of complications such as urinary retention, nausea, headache, local anesthetic systemic toxicity (LAST), bradycardia, hypotension, nausea, vomiting, respiratory depression or any other complication will be recorded.

    Time frame: 24 hours postoperatively

07

Study locations

1 of 1 sites recruiting
  • Tanta University
    Tanta, El-Gharbia 31527, Egypt
    • Aya Allah H Elbahy, Master · Contact · 3ed2318@gmail.com · 00201098959739
    • Osama M Shalaby, MD · Sub investigator
    • Ahmed A El-Daba, MD · Sub investigator
    • Rabab M Mohamed, MD · Sub investigator
    • Hesham I El-Tatawy, MD · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07074730
Lead sponsor
Tanta University
Responsible party
Aya Allah Hamdy Elbahy (Assistant lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt., Tanta University) — Principal investigator
First posted
Jul 20, 2025
Start date
Jul 19, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Jul 22, 2025

Study contacts

Aya Allah H Elbahy, Master
Contact
3ed2318@gmail.com
00201098959739

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion